Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:MNOV
- CUSIP: N/A
- Web: medicinova.com
Capitalization:- Market Cap: $183.41 million
- Outstanding Shares: 34,540,000
Average Prices:- 50 Day Moving Avg: $5.39
- 200 Day Moving Avg: $5.74
- 52 Week Range: $4.85 - $7.78
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -15.62
- P/E Growth: -0.76
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.95 per share
- Price / Book: 5.59
Profitability:- EBIDTA: ($10,500,000.00)
- Return on Equity: -29.92%
- Return on Assets: -26.19%
Debt:- Current Ratio: 21.88%
- Quick Ratio: 21.88%
Misc:- Average Volume: 44,727 shs.
- Beta: 0.04
- Short Ratio: 37.46
Frequently Asked Questions for MediciNova (NASDAQ:MNOV)
What is MediciNova's stock symbol?
MediciNova trades on the NASDAQ under the ticker symbol "MNOV."
How were MediciNova's earnings last quarter?
MediciNova, Inc. (NASDAQ:MNOV) released its earnings results on Thursday, October, 29th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.04. View MediciNova's Earnings History.
Who are some of MediciNova's key competitors?
Some companies that are related to MediciNova include BioSpecifics Technologies Corp (BSTC), Ra Pharmctl (RARX), Merus NV (MRUS), BioTime (BTX), Edge Therapeutics (EDGE), Corbus Pharmaceuticals Holdings (CRBP), Rigel Pharmaceuticals (RIGL), GlycoMimetics (GLYC), Minerva Neurosciences (NERV), AVEO Pharmaceuticals (AVEO), Oxford BioMedica plc (OXB), Ardelyx (ARDX), Immune Design Corp. (IMDZ), DURECT Corporation (DRRX), Circassia Pharmaceuticals PLC (CIR), Catalyst Pharmaceuticals (CPRX), Akebia Therapeutics (AKBA) and Pieris Pharmaceuticals (PIRS).
Who are MediciNova's key executives?
MediciNova's management team includes the folowing people:
- Jeffrey Himawan Ph.D., Independent Chairman of the Board
- Yuichi Iwaki M.D., Ph.D., President, Chief Executive Officer, Director
- Ryan Selhorn, Chief Financial Officer
- Geoffrey G. O'Brien J.D., Vice President
- Masatsune Okajima, Vice President, Head - Japanese Office
- Kazuko Matsuda M.D., Ph.D., Chief Medical Officer
- Yoshio Ishizaka, Independent Director
- Yutaka Kobayashi, Independent Director
Who owns MediciNova stock?
MediciNova's stock is owned by a variety of of retail and institutional investors. Top institutional investors include
KISSEI PHARMACEUTICAL COMPANY ., LTD.
(4.10%). Company insiders that own MediciNova stock include Geoffrey Obrien and Yutaka Kobayashi. View Institutional Ownership Trends for MediciNova.
How do I buy MediciNova stock?
Shares of MediciNova can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MediciNova's stock price today?
One share of MediciNova stock can currently be purchased for approximately $5.31.
MarketBeat Community Rating for MediciNova (NASDAQ MNOV)MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for MediciNova (NASDAQ:MNOV) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for MediciNova (NASDAQ:MNOV)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 4/18/2017 | Credit Suisse Group | Initiated Coverage | Outperform -> Outperform | | High |  |
| 3/21/2016 | Ladenburg Thalmann Financial Services | Boost Price Target | Buy | $6.00 -> $11.00 | N/A | |
(Data available from 7/26/2015 forward)
Earnings History for MediciNova (NASDAQ:MNOV)Earnings History by Quarter for MediciNova (NASDAQ MNOV)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/29/2015 | Q3 2015 | ($0.10) | ($0.06) | | | View | N/A | |
| 7/30/2015 | Q2 2015 | ($0.10) | ($0.09) | | | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.11) | ($0.14) | $0.37 million | | View | N/A | |
| 5/8/2013 | Q1 2013 | ($0.13) | ($0.14) | $0.31 million | | View | N/A | |
| 11/8/2012 | Q312 | | ($0.14) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for MediciNova (NASDAQ:MNOV)2017 EPS Consensus Estimate: ($0.38)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.10) | ($0.10) | ($0.10) |
| Q2 2017 | 1 | ($0.10) | ($0.10) | ($0.10) |
| Q3 2017 | 1 | ($0.09) | ($0.09) | ($0.09) |
| Q4 2017 | 1 | ($0.09) | ($0.09) | ($0.09) |
(Data provided by Zacks Investment Research)
Dividend History for MediciNova (NASDAQ:MNOV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for MediciNova (NASDAQ:MNOV)Insider Ownership Percentage: 15.20%
Institutional Ownership Percentage: 22.26%
Insider Trades by Quarter for MediciNova (NASDAQ:MNOV)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/15/2017 | Yutaka Kobayashi | Director | Buy | 1,000 | $5.60 | $5,600.00 | |
| 5/12/2017 | Yutaka Kobayashi | Director | Buy | 24,000 | $5.62 | $134,880.00 | |
| 9/15/2016 | Yutaka Kobayashi | Director | Buy | 11,800 | $6.44 | $75,992.00 | |
| 9/9/2016 | Yutaka Kobayashi | Director | Buy | 10,000 | $6.67 | $66,700.00 | |
| 7/5/2016 | Geoffrey Obrien | VP | Sell | 3,300 | $8.00 | $26,400.00 | |
| 12/10/2014 | Yutaka Kobayashi | Director | Buy | 12,000 | $3.54 | $42,480.00 | |
| 11/26/2014 | Yutaka Kobayashi | Director | Buy | 10,000 | $3.07 | $30,700.00 | |
| 11/20/2014 | Yutaka Kobayashi | Director | Buy | 13,000 | $3.19 | $41,470.00 | |
| 11/19/2014 | Yoshio Ishizaka | Director | Buy | 5,000 | $2.86 | $14,300.00 | |
| 9/11/2014 | Yutaka Kobayashi | Director | Buy | 10,000 | $2.95 | $29,500.00 | |
| 9/3/2014 | Yutaka Kobayashi | Director | Buy | 15,000 | $2.66 | $39,900.00 | |
| 12/12/2013 | Tatsuo Izumi | Director | Sell | 71,270 | $2.10 | $149,667.00 | |
| 11/18/2013 | Tatsuo Izumi | Director | Buy | 1,270 | $2.21 | $2,806.70 | |
| 5/21/2013 | Arlene Morris | Director | Sell | 8,800 | $3.28 | $28,864.00 | |
| 5/13/2013 | Tatsuo Izumi | Director | Buy | 158,730 | $3.15 | $499,999.50 | |
(Data available from 1/1/2013 forward)
Headline Trends for MediciNova (NASDAQ:MNOV)
Latest Headlines for MediciNova (NASDAQ:MNOV)
| Source: |
|
| Date | Headline |
|---|
 | MediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois
finance.yahoo.com - June 5 at 7:15 PM |
 | MediciNova, Inc. (MNOV) Director Yutaka Kobayashi Purchases 24,000 Shares
www.americanbankingnews.com - May 15 at 7:50 PM |
| FY2017 Earnings Forecast for MediciNova, Inc. (MNOV) Issued By Zacks Investment Research
www.americanbankingnews.com - May 8 at 9:46 AM |
| MediciNova (MNOV) Receives Daily Media Sentiment Rating of -0.20
www.americanbankingnews.com - May 4 at 10:36 AM |
| Somewhat Positive Media Coverage Very Likely to Impact MediciNova (MNOV) Share Price
www.americanbankingnews.com - April 27 at 4:34 PM |
 | Pre-Open Stock Movers 04/26: (AKBA) (IRTB) (TWTR) Higher; (X) (STX) (CREE) Lower (more...)
www.streetinsider.com - April 26 at 6:43 PM |
 | Mid-Morning Market Update: Markets Edge Higher; Twitter Earnings Beat Views
www.nasdaq.com - April 26 at 6:43 PM |
| MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) …
finance.yahoo.com - April 26 at 6:43 PM |
| MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston
finance.yahoo.com - April 26 at 6:43 PM |
| MediciNova (MNOV) Earning Very Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 23 at 8:08 AM |
| MediciNova (MNOV) Receives Daily Coverage Optimism Rating of 0.02
www.americanbankingnews.com - April 20 at 9:47 PM |
| MediciNova, Inc. (MNOV) Coverage Initiated at Credit Suisse Group AG
www.americanbankingnews.com - April 18 at 4:26 PM |
| MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017
www.nasdaq.com - April 10 at 10:25 AM |
| MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois
finance.yahoo.com - April 10 at 10:25 AM |
 | MediciNova's MN-166: Good Trial, But What About Generic Riluzole?
seekingalpha.com - March 29 at 9:43 AM |
| MNOV: MN-166 Making Progress in Numerous Indications…
finance.yahoo.com - February 27 at 6:04 PM |
| MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies in Zurich, Switzerland
finance.yahoo.com - February 27 at 6:04 PM |
| MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - February 16 at 6:10 PM |
| MEDICINOVA INC Files SEC form 10-K, Annual Report
biz.yahoo.com - February 14 at 8:09 PM |
 | MediciNova Announces MN-166 (ibudilast) ALS...
www.benzinga.com - February 8 at 1:14 AM |
| MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston
finance.yahoo.com - February 7 at 7:55 PM |
| Leading addiction researchers discuss MN-166 in symposium on novel pharmacotherapies to treat substance use disorders
www.nasdaq.com - February 6 at 6:41 PM |
| MediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine Dependence Presented at the 50th Winter Conference on Brain Research
finance.yahoo.com - February 6 at 6:41 PM |
| MediciNova to Attend Mizuho Healthcare Conference in New York
finance.yahoo.com - February 1 at 7:31 PM |
| Medicinova (MNOV) Positive MN-166 Data Published in Neuropsychopharmacology
www.streetinsider.com - January 23 at 6:55 PM |
| MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence
finance.yahoo.com - January 23 at 6:55 PM |
| MNOV: Phase 2b Trial of MN-166 in Progressive MS Will Continue to Conclusion
finance.yahoo.com - December 22 at 6:54 PM |
| Medicinova (MNOV) Announces EU Orphan Medicinal Product Designation for MN-166
www.streetinsider.com - December 21 at 9:40 AM |
| Medicinova (MNOV) Says Phase 2b Trial of MN-166 in MS Will Continue Following DSMB Review
www.streetinsider.com - December 20 at 12:30 PM |
 | 6:09 am MediciNova announces the phase 2b trial of MN-166 in progressive MS will continue as planned following DSMB review of interim efficacy analysis; expects to receive final data analysis from the study in the 2H17
us.rd.yahoo.com - December 19 at 10:14 AM |
| 6:00 am MediciNova announces exploratory interim clinical outcomes data from clinical trial of MN-166 (ibudilast) in ALS presented at the 27th International Symposium on ALS/MND
finance.yahoo.com - December 9 at 9:08 AM |
| MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 27th International Symposium on ALS/MND in Dublin, Ireland
finance.yahoo.com - December 9 at 9:08 AM |
| MediciNova to Present at the Piper Jaffray Healthcare Conference in New York
finance.yahoo.com - November 14 at 10:20 AM |
| MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - November 10 at 5:56 PM |
| MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for MN-166 …
finance.yahoo.com - November 10 at 8:59 AM |
| MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 27th International Symposium on ALS/MND in Dublin, Ireland
finance.yahoo.com - October 31 at 12:53 PM |
| MEDICINOVA INC Financials
finance.yahoo.com - October 29 at 5:55 PM |
| MNOV: Interim Analysis of MN-166 in Progressive MS in 4Q16; ODD granted to MN-166 for ALS
finance.yahoo.com - October 27 at 6:17 PM |
| Medicinova (MNOV) Updates on FY16 Outlook
www.streetinsider.com - October 26 at 6:14 PM |
| Medicinova's (MNOV) MN-166 Granted FDA Orphan Drug Designation as ALS Treatment
www.streetinsider.com - October 12 at 11:30 AM |
| MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis
finance.yahoo.com - October 12 at 11:30 AM |
| MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - September 16 at 5:59 PM |
| MNOV: Interim Analysis For Phase 2b Trial of MN-166 in Progressive MS in 4Q16
finance.yahoo.com - July 29 at 12:00 PM |
| MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis
www.nasdaq.com - July 26 at 6:33 PM |
 | NVCR Up On FDA Nod, PeriCoach Now Available OTC, FDA Panel Backs GP2015
www.rttnews.com - July 14 at 6:29 PM |
| Medicinova (MNOV) Announces Presentation of MN-166 Results in AUD
www.streetinsider.com - June 30 at 9:07 AM |
MediciNova (MNOV) Chart for Wednesday, July, 26, 2017
